Precision Medicine in Oncology
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OncLive Global Expo
Giants of Cancer Care
Precision Medicine in Oncology
<< View More Conferences
2017 ESMO Congress
Oncology Conference Multimedia
View more videos >>
Dr. Garassino on the PACIFIC Trial for NSCLC
Dr. Besse on the Combination of Treatments for NSCLC
Dr. Bauml Discusses the FLAURA Study in NSCLC
Oncology Conference Articles
Neutrophil to Lymphocyte Ratio Predicts Survival in Metastatic Melanoma
The neutrophil-to-lymphocyte ratio is an independent factor for overall survival in patients with metastatic melanoma, whether they receive targeted therapy or immunotherapy.
Cabozantinib, Nivolumab Active in Metastatic Urothelial Carcinoma
Cabozantinib and nivolumab with or without ipilimumab show activity in genitourinary tumors, particularly urothelial carcinoma, and have manageable safety profiles.
Study Finds Hyperprogression After Immunotherapy in NSCLC Subset
Although anti-PD-1/PD-L1 immunotherapy has greatly improved the treatment of patients with non–small cell lung cancer and is generally well-tolerated, the therapy backfires in a newly defined subset of patients who experience accelerated tumor growth indicative of hyperprogressive disease.
Neoadjuvant Dabrafenib/Trametinib Leads to High pCR Rates in Bulky Resectable Melanoma, But Recurrences Are Common
Nearly half of patients with resectable stage IIIB/C BRAF V600-mutant melanoma achieved pathologic complete response with neoadjuvant combination therapy consisting of dabrafenib (Tafinlar) and trametinib (Mekinist).
Mixed Results for Pembrolizumab in Phase III HNSCC Study
Pembrolizumab (Keytruda) reduced the risk of death compared with standard of care therapy in patients with relapsed/metastatic head and neck squamous cell carcinoma, but the difference fell just shy of statistical significance.
Disease-Free Survival Gains Reported for Vemurafenib in Stage IIC-IIIB Melanoma
Adjuvant therapy with vemurafenib for high-risk melanoma led to mixed results, as patients with stage IIIC or later did not benefit, but those with earlier stage disease did.
Combined Niraparib and Bevacizumab Shows Promising Activity in Recurrent Ovarian Cancer
The combination of bevacizumab plus niraparib demonstrated clinical activity in women with relapsed, platinum-sensitive epithelial ovarian cancer and had a manageable toxicity profile.
Pazopanib Regimen Active, But Misses Mark in Leiomyosarcoma
Although second-line treatment with combined pazopanib and gemcitabine demonstrated disease control in the majority of patients with metastatic or relapsed uterine or soft tissue leiomyosarcomas, the phase II UNICANCER SARCOME 11 study did not meet statistical endpoints and is considered a negative trial.
PFR Unaffected by Sequence of Cytoreductive Nephrectomy and Sunitinib in Patients With Synchronous mRCC
Treating primary tumors by administering targeted therapy with sunitinib (Sutent) prior to cytoreductive nephrectomy did not improve the progression-free rate at 28 weeks over a sequence of immediate CN followed by sunitinib in patients with synchronous metastatic renal cell carcinoma.
Nivolumab Superior to Ipilimumab as Adjuvant Therapy for Stage III/IV Resected Melanoma
Nivolumab (Opdivo) may represent a new standard option for adjuvant therapy for patients with resected stage IIIB/C and IV melanoma, whether or not they have a BRAF mutation. In a comparison with current standard high-dose ipilimumab (Yervoy), nivolumab demonstrated a significant improvement in relapse-free survival.
Nivolumab/Ipilimumab Improves Survival Versus Sunitinib in mRCC
The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) was superior to sunitinib (Sutent) monotherapy as first-line treatment of advanced or metastatic renal cell carcinoma.
Ramucirumab Improves PFS in Platinum-Refractory Urothelial Carcinoma
Ramucirumab (Cyramza) plus docetaxel improved progression-free survival over docetaxel alone in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy.
CABOSUN Update Affirms PFS Advantage With Cabozantinib Over Sunitinib in Advanced RCC
Patients with untreated advanced renal cell carcinoma lived significantly longer without disease progression when they received the multikinase inhibitor cabozantinib (Cabometyx) as initial therapy versus sunitinib (Sutent).
Combination Lenvatinib/Pembrolizumab Has Antitumor Activity in Metastatic Clear Cell RCC
Lenvatinib (Lenvima) combined with pembrolizumab (Keytruda) demonstrated promising antitumor activity in patients with metastatic clear cell renal cell carcinoma.
Atezolizumab Plus Bevacizumab Shows Encouraging Clinical Activity in mRCC
Atezolizumab with bevacizumab provided improved progression-free survival over sunitinib in patients with untreated metastatic renal cell carcinoma.
Frontline Dabrafenib/Trametinib Effective for BRAF+ NSCLC
Frontline treatment with the combination of dabrafenib and trametinib showed promising clinical efficacy for patients with
-mutant metastatic non–small cell lung cancer.
Adjuvant Dabrafenib/Trametinib Doubles RFS for BRAF+ Melanoma
Adjuvant treatment with dabrafenib and trametinib reduced the risk of relapse or death by 53% compared with placebo for patients with stage III
Pembrolizumab Shows Greater Long-Term Benefits Versus Chemo for Urothelial Carcinoma
Mature results from the phase III KEYNOTE-045 study presented at the 2017 ESMO Congress demonstrated that overall survival with pembrolizumab (Keytruda) continued to improve compared to chemotherapy in patients with recurrent, advanced urothelial carcinoma.
Enhanced Post-Surgery Surveillance Not Linked to Longer OS in NSCLC
Expanding surveillance after surgery for early-stage non–small cell lung cancer from chest x-ray to follow-up with PET-CT scan did not improve overall survival.
PD-1/IDO Combination Active in Advanced Melanoma
A majority of patients with advanced melanoma responded to the combination of pembrolizumab and the investigational IDO1 inhibitor epacadostat.
Neoadjuvant Nivolumab Reduces Tumor Size Regardless of HPV Status in Head and Neck Cancer
Two doses of nivolumab given about 1 month prior to surgery are well tolerated and reduces tumor size in about half of patients with squamous cell carcinoma of the head and neck.
Abemaciclib Improves PFS for HR+/HER2- Advanced Breast Cancer
The addition of abemaciclib to anastrozole or letrozole reduced the risk of progression or death by 46% compared with the non-steroidal aromatase inhibitors alone for previously untreated patients with HER2-negative, HR-positive advanced breast cancer.
Denosumab May Help Some With Bone Tumors Avoid Surgery
More than one-third of patients with resectable giant cell tumor of bone avoided surgery and nearly half had less morbidity with surgery when treated with denosumab (Xgeva).
Nab-Paclitaxel Alone and With Durvalumab Shows Promise in NSCLC
Nab-paclitaxel (Abraxane) monotherapy has efficacy in patients with pretreated advanced nonsquamous non-small cell lung cancer that is not improved by the addition of CC-486.
Immune System Priming Prior to Checkpoint Blockade Improves Response in Metastatic TNBC
Turning a nonimmunogenic (“cold”) tumor into an immunogenic (“hot”) tumor appears feasible in patients with metastatic triple negative breast cancer, thereby improving sensitivity to immune therapy with nivolumab.
Binimetinib Adds to Encorafenib PFS Benefit for BRAF+ Melanoma
The combination of encorafenib and binimetinib demonstrated significant improvements in PFS compared with single-agent vemurafenib or encorafenib for patients with
-mutant advanced melanoma.
Liquid Biopsy for Mutation Burden Predicts PFS in NSCLC Immunotherapy
A liquid biopsy that measures tumor mutational burden showed promise as an aid for predicting benefit in patients with non-small cell lung cancer treated with a checkpoint inhibitor.
Nivolumab Past One Year Improves Progression-Free Survival in Pretreated NSCLC
Continuous treatment with nivolumab until disease progression was associated with superior progression-free survival compared with a 1-year fixed duration treatment for patients with previously treated advanced non-small cell lung cancer.
Durvalumab "Game-Changer" for Locally Advanced Lung Cancer
The PD-L1 inhibitor durvalumab improved median progression-free survival by 11.2 months compared with placebo for patients with locally advanced, unresectable stage III lung cancer who had not progressed following chemoradiotherapy.
Frontline Osimertinib Doubles PFS for EGFR+ NSCLC
Frontline osimertinib improved median progression-free survival by 18.9 months, representing a 54% reduction in the risk of progression or death compared with standard therapy for patients with EGFR-mutant non–small cell lung caner.
Taselisib, Letrozole Combination Active for ER+, HER2- Early Breast Cancer
Taselisib added to standard letrozole (Femara) improved the objective response rate compared to letrozole with a placebo in postmenopausal women with estrogen receptor-positive and HER2-negative early breast cancer.
Alectinib Highly Effective for ALK+ NSCLC With CNS Metastases
Treatment with alectinib (Alecensa) demonstrated promising efficacy for patients with
-translocated non–small cell lung cancer with central nervous system metastases in both the first- and second-line setting.
Maintenance Rucaparib Highly Effective Across Ovarian Cancer Subtypes
Maintenance treatment with the PARP inhibitor rucaparib improved median progression-free survival by 11.2 months compared with placebo for patients with BRCA-mutant platinum-sensitive ovarian cancer.
FDA Approvals in Non-Hodgkin Lymphoma, Breast Cancer, GVHD, and Mesothelioma
Imetelstat Provides Durable Transfusion Independence in Lower-Risk Relapsed/Refractory MDS
Elotuzumab Triplet Continues to Show Survival Benefit in Relapsed/Refractory Myeloma
New Macrophage Immune Checkpoint Strategy Shows Promise in AML and MDS
Second-Generation FLT3 Inhibitors Are Future of Relapsed/Refractory FLT3-Mutant AML Treatment
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2019
Intellisphere, LLC. All Rights Reserved.